ProfileGDS5678 / 1426506_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 57% 64% 57% 57% 56% 55% 57% 57% 57% 57% 57% 55% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4716456
GSM967853U87-EV human glioblastoma xenograft - Control 23.4543357
GSM967854U87-EV human glioblastoma xenograft - Control 33.822364
GSM967855U87-EV human glioblastoma xenograft - Control 43.4052857
GSM967856U87-EV human glioblastoma xenograft - Control 53.4016357
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4946956
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4531755
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4358157
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4318757
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4409957
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4369457
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4273557
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4018255
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4431957